Hyperchylomicronaemia is a rare inherited disorder where the body loses its ability to break down fats properly, causing dangerous fat levels in the blood that can lead to severe complications including life-threatening inflammation of the pancreas.

Managing a Rare Fat Metabolism Disorder

The treatment of hyperchylomicronaemia, also known as familial chylomicronemia syndrome, focuses on controlling the extremely high levels of triglycerides in the blood and preventing serious complications. The main goal is to reduce symptoms, protect vital organs like the pancreas, and improve the quality of life for people living with this challenging condition. Treatment success depends heavily on how early the condition is identified and how strictly patients follow dietary restrictions.^[1]

Because this is a genetic disorder affecting an essential enzyme called lipoprotein lipase, which normally breaks down fats in the bloodstream, management requires a lifelong commitment. The condition can appear in infancy or childhood, though some people don’t develop symptoms until adulthood. Each person’s treatment plan must be tailored to their specific situation, symptom severity, and how their body responds to interventions.^[2]

Medical societies and clinical experts agree that diet forms the cornerstone of managing hyperchylomicronaemia. Beyond these standard approaches, researchers are actively investigating new therapies through clinical trials, offering hope for better treatment options in the future. These experimental treatments target the underlying biological problems in ways that dietary changes alone cannot achieve.^[9]

Standard Treatment Approaches

The primary and most critical treatment for hyperchylomicronaemia is a severely restricted fat diet. Healthcare providers typically recommend that patients consume no more than 20 grams of fat per day. To put this in perspective, the average diet in Western countries contains up to 45% of calories from fat, which would be completely inappropriate for someone with this condition. Twenty grams of fat is roughly equivalent to four teaspoons of margarine, two glasses of whole milk, or a four-ounce serving of meat. This represents a dramatic reduction from what most people normally eat.^[5]

This extreme dietary restriction works because it directly reduces the amount of fat particles called chylomicrons that enter the bloodstream after eating. When people with hyperchylomicronaemia eat fat, these chylomicrons accumulate in their blood because their bodies cannot break them down properly. By limiting fat intake, the buildup is minimized, which in turn reduces triglyceride levels and helps prevent the painful and dangerous complications of the disease.^[8]

Following such a restricted diet requires careful planning and often the guidance of a registered dietitian who specializes in this condition. Patients need to learn how to read food labels, identify hidden fats in foods, and prepare meals that meet their nutritional needs while staying within the strict fat limit. Many everyday foods that others take for granted become off-limits or must be consumed in tiny amounts.^[14]

Traditional lipid-lowering medications, such as fibrates and omega-3 fatty acids, are commonly used to manage high triglycerides in the general population. However, in hyperchylomicronaemia, these medications often prove ineffective or provide only minimal benefit. The condition is described as “treatment-refractory,” meaning it does not respond well to standard pharmacological therapies. Fibrates like fenofibrate work by activating specific receptors that regulate fat metabolism, but when the underlying enzyme lipoprotein lipase is absent or non-functional, these drugs cannot compensate for the defect.^[4]

In some childhood cases, physicians have used medications like ciprofibrate as part of the treatment regimen alongside dietary restrictions. While these drugs may offer some modest reduction in triglyceride levels in certain patients, they are not considered a primary or reliable solution. The response varies greatly from person to person, and many patients see little to no improvement with medication alone.^[11]

When acute complications occur, particularly pancreatitis (severe inflammation of the pancreas), immediate medical intervention is essential. Treatment for pancreatitis episodes typically involves hospitalization, complete avoidance of food and drink by mouth to rest the pancreas, intravenous fluids, pain management, and close monitoring. Some patients experience recurrent episodes throughout their lives, each one potentially life-threatening and causing progressive damage to the pancreas.^[10]

Long-term management also includes regular monitoring through blood tests to measure triglyceride levels. Normal triglyceride levels are below 150 milligrams per deciliter, but people with hyperchylomicronaemia commonly have levels exceeding 1,000 milligrams per deciliter, sometimes reaching levels ten times higher than normal even when fasting. These measurements help doctors assess how well the dietary restrictions are working and whether any adjustments are needed.^[13]

Treatment in Clinical Trials

Because standard treatments for hyperchylomicronaemia are limited and often inadequate, researchers have been actively developing and testing new therapeutic approaches through clinical trials. These experimental treatments aim to address the fundamental problem at the molecular level, offering possibilities that diet alone cannot achieve. Several promising candidates have emerged in recent years, representing different strategies to manage this challenging disorder.^[9]

One of the most extensively studied experimental treatments is volanesorsen, a novel type of medication called an antisense oligonucleotide. This drug works by targeting a specific protein in the blood called apolipoprotein C-III (ApoC-III). Normally, ApoC-III inhibits the breakdown of triglycerides by interfering with lipoprotein lipase activity. In people with hyperchylomicronaemia who already have deficient or absent lipoprotein lipase, the presence of ApoC-III makes matters even worse by further blocking whatever minimal fat-processing ability might remain.^[9]

Volanesorsen is designed to reduce the production of ApoC-III in the liver, thereby removing this additional obstacle to fat metabolism. The medication is administered as an injection under the skin. Clinical trials have tested volanesorsen in patients with familial chylomicronemia syndrome, examining whether reducing ApoC-III levels could effectively lower triglycerides and reduce the frequency of pancreatitis episodes. The drug represents a sophisticated approach that uses genetic technology to modify protein production in a targeted way.^[9]

Results from clinical trials of volanesorsen showed that many patients experienced substantial reductions in their triglyceride levels compared to those who received a placebo. Some participants saw their dangerously high triglyceride levels drop significantly, and there were reports of fewer pancreatitis episodes among treated patients. These findings generated considerable excitement in the medical community because they demonstrated that a pharmacological intervention could make a meaningful difference in this difficult-to-treat condition.^[9]

However, the development and approval of volanesorsen has faced challenges. One significant concern that emerged during clinical trials was the drug’s effect on blood platelets, the cells responsible for blood clotting. Some patients developed low platelet counts, a condition called thrombocytopenia, which can increase the risk of bleeding. This side effect requires careful monitoring through regular blood tests, and in some cases, treatment must be adjusted or discontinued if platelet levels drop too low. The balance between the drug’s benefits and its potential risks has been a central consideration in regulatory decisions about its approval in different countries.^[9]

Another experimental therapy being investigated is olezarsen, also known by the brand name Tryngolza. Like volanesorsen, olezarsen is an antisense oligonucleotide that targets ApoC-III production. This newer drug was designed with improvements intended to enhance effectiveness and potentially reduce side effects. Clinical trials have been conducted to evaluate olezarsen’s safety profile and its ability to lower triglycerides in patients with severe hypertriglyceridemia, including those with hyperchylomicronaemia.^[3]

Gene therapy represents another frontier in research for hyperchylomicronaemia. Because the condition results from mutations in specific genes (most commonly the gene encoding lipoprotein lipase), scientists have explored whether it might be possible to introduce functional copies of the gene into patients’ cells. One experimental gene therapy approach involved using a modified virus to deliver working lipoprotein lipase genes to muscle tissue, where they could produce the missing enzyme.^[3]

A gene therapy product called alipogene tiparvovec was developed specifically for lipoprotein lipase deficiency. This treatment received regulatory approval in Europe in 2012, marking a significant milestone as one of the first gene therapies approved anywhere in the world. The therapy was administered as a series of injections into the leg muscles. The goal was to enable those muscle cells to produce functional lipoprotein lipase enzyme, which would then enter the bloodstream and help break down triglycerides.^[3]

However, despite the scientific achievement and initial approval, the commercial availability of this gene therapy faced numerous obstacles. Issues related to manufacturing complexity, high costs, limited patient numbers, and questions about long-term effectiveness ultimately led to the product being withdrawn from the market. The experience with alipogene tiparvovec has provided valuable lessons for the field of gene therapy, even though it did not become a widely available treatment option for patients.^[3]

Clinical trials for hyperchylomicronaemia treatments are conducted at specialized medical centers, often at academic hospitals with expertise in lipid disorders and rare diseases. These trials may be available in various locations including the United States, Europe, and other regions. Patients interested in participating typically must meet specific eligibility criteria, such as having confirmed genetic mutations causing the condition, documented high triglyceride levels, and a history of symptoms like recurrent pancreatitis. Participation in clinical trials offers potential access to cutting-edge treatments before they become widely available, though it also involves uncertainties and risks as the therapies are still being evaluated.^[9]

Most common treatment methods

• Very Low-Fat Diet
  • Restriction to no more than 20 grams of fat per day
  • Requires careful meal planning and label reading
  • Supplementation with fat-soluble vitamins (A, D, E, K) and minerals
  • Guidance from specialized dietitians
  • Lifelong dietary commitment required
• Supportive Pharmacotherapy
  • Fibrates such as fenofibrate or ciprofibrate
  • Omega-3 fatty acid supplements
  • Often minimally effective due to treatment-refractory nature
  • Used as adjunct to dietary management
• Acute Pancreatitis Management
  • Hospitalization for severe episodes
  • Nothing by mouth to rest the pancreas
  • Intravenous fluid replacement
  • Pain control medications
  • Close monitoring of complications
• Experimental Antisense Oligonucleotide Therapy
  • Volanesorsen targeting apolipoprotein C-III
  • Olezarsen (Tryngolza) as newer agent
  • Administered as subcutaneous injections
  • Requires monitoring for platelet count reduction
  • Tested in Phase II and Phase III clinical trials
• Gene Therapy Approaches
  • Alipogene tiparvovec (no longer commercially available)
  • Delivery of functional lipoprotein lipase gene
  • Ongoing research into improved gene therapy methods